{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:49:47Z","timestamp":1780472987543,"version":"3.54.1"},"reference-count":11,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The study was aimed to compare hybrid arc and volumetric-modulated arc therapy treatment plans for fractionated stereotactic radiotherapy of brain tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Treatment plans of 22 patients were studied. Hybrid arc and volumetric-modulated arc therapy plans were generated using Brainlab iPlanDose and Varian Eclipse treatment planning systems, respectively, with 6 MV photon beams on a Varian TrueBeam STx linear accelerator (Palo Alto, CA). Prescription dose was 54 Gy. The fractionation was 1.8 Gy per fraction and 30 fractions in total, or 2 Gy per fraction and 27 fractions in total. Planning target volume ranged from 2.4 to 28.6 cm\n                      <jats:sup>3<\/jats:sup>\n                      . Dose conformity index, gradient index, homogeneity index, and maximum doses in organs at risk were compared. Wilcoxon signed rank test was used to determine statistical significance in paired comparison.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Conformity indexes of hybrid arc and volumetric-modulated arc therapy plans are 1.10 \u00b1 0.10 and 1.14 \u00b1 0.07, respectively ( P = .4); gradient indexes are 5.02 \u00b1 1.20 and 5.64 \u00b1 1.28, respectively ( P = .0001); homogeneity indexes are 1.02 \u00b1 0.01 and 1.05 \u00b1 0.01, respectively ( P = .0001); brainstem maximum doses are 53.87 \u00b1 1.63 Gy and 54.06 \u00b1 3.17 Gy, respectively ( P = .1); and optic chiasm maximum doses are 53.86 \u00b1 1.28 Gy and 53.95 \u00b1 1.81, respectively ( P = .4). The monitor unit efficiencies of hybrid arc and volumetric-modulated arc therapy plans are 2.57 \u00b1 0.25 MU\/cGy and 2.68 \u00b1 0.24 MU\/cGy, respectively ( P = .2). The differences of conformity index, gradient index, and homogeneity index between hybrid arc and volumetric-modulated arc therapy plans are small: 0.08 \u00b1 0.05, 0.65 \u00b1 0.46, and 0.02 \u00b1 0.01, respectively. The maximum doses in organs at risks are similar between hybrid arc and volumetric-modulated arc therapy plans. Hybrid arc and volumetric-modulated arc therapy plans, which have similar monitor unit efficiencies, present similar dosimetric results in the fractionated intracranial radiotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1533033818802804","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:13:16Z","timestamp":1540167196000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of Hybrid Arc and Volumetric-Modulated Arc Therapy Treatment Plans for Fractionated Stereotactic Intracranial Radiotherapy"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1430-8148","authenticated-orcid":false,"given":"Jun","family":"Li","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"To","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie","family":"Gunn","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,10,21]]},"reference":[{"key":"bibr1-1533033818802804","doi-asserted-by":"publisher","DOI":"10.1177\/153303460900800506"},{"key":"bibr2-1533033818802804","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/13776022"},{"key":"bibr3-1533033818802804","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-016-0632-8"},{"key":"bibr4-1533033818802804","doi-asserted-by":"publisher","DOI":"10.3233\/XST-160561"},{"key":"bibr5-1533033818802804","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-016-0634-6"},{"key":"bibr6-1533033818802804","doi-asserted-by":"publisher","DOI":"10.1007\/s13246-015-0397-7"},{"key":"bibr7-1533033818802804","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000418"},{"key":"bibr8-1533033818802804","doi-asserted-by":"publisher","DOI":"10.1016\/j.meddos.2015.06.003"},{"key":"bibr9-1533033818802804","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.08.030"},{"key":"bibr10-1533033818802804","doi-asserted-by":"publisher","DOI":"10.1016\/j.meddos.2012.02.001"},{"key":"bibr11-1533033818802804","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-120"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1533033818802804","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1533033818802804","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1533033818802804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:02:42Z","timestamp":1777701762000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1533033818802804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":11,"alternative-id":["10.1177\/1533033818802804"],"URL":"https:\/\/doi.org\/10.1177\/1533033818802804","relation":{},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,1]]},"article-number":"1533033818802804"}}